-
3 weeks ago | 
pharmacytimes.com | Joshua K. Sabari |Kennedy Ferruggia
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Joshua Sabari, MD, assistant professor of medicine and medical oncology at Perlmutter Cancer Center NYU Langone Health, presented data that examined the development of zongertinib (BI 1810631; Boehringer Ingelheim), a HER2-selective tyrosine kinase inhibitor (TKI) for the treatment of HER2-mutant advanced non-small cell lung cancer (NSCLC).
-
Nov 25, 2024 | 
targetedonc.com | Joshua K. Sabari
November 25, 2024Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them with second-line topotecan and CAV regimens, while discussing the potential of various compounds for platinum-sensitive vs platinum-resistant subgroups.
-
Nov 25, 2024 | 
targetedonc.com | Joshua K. Sabari
November 25, 2024Joshua K.
-
Nov 18, 2024 | 
targetedonc.com | Joshua K. Sabari
November 18, 2024Joshua K. Sabari, MD, describes the mechanism of action of lurbinectedin as a synthetic alkaloid that binds to guanine residues in the minor groove of DNA, forming adducts that disrupt DNA repair mechanisms and promote apoptosis in cancer cells, noting that its action contrasts with traditional alkylating agents by specifically interfering with DNA-protein interactions and transcription processes.
-
Nov 18, 2024 | 
targetedonc.com | Joshua K. Sabari
November 18, 2024Joshua K. Sabari, MD, evaluates the potential of ifinatamab deruxtecan in combination with atezolizumab, with or without platinum-based chemotherapy, as first-line induction or maintenance therapy in ES-SCLC, emphasizing that statistically significant end points such as improved PFS and OS would be essential for clinical application in this patient population.
-
Nov 11, 2024 | 
targetedonc.com | Joshua K. Sabari
November 11, 2024Joshua K. Sabari, MD, discusses the potential treatment synergies expected from combining MK-6070, a trispecific T-cell engager, with ifinatamab deruxtecan, noting that specific patient and disease factors (eg, tumor expression profiles and previous treatment responses) could influence the decision to pursue dual T-cell engager therapy in early clinical development.
-
Nov 11, 2024 | 
targetedonc.com | Joshua K. Sabari
November 11, 2024Joshua K. Sabari, MD, discusses how the dosing schedule of ifinatamab deruxtecan offers advantages in terms of simplicity and treatment adherence vs topotecan and lurbinectedin, suggesting that it may enhance the overall quality of life for patients undergoing treatment for SCLC.
-
Nov 4, 2024 | 
targetedonc.com | Joshua K. Sabari
November 4, 2024Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that a 12-month OS is clinically meaningful for this patient population following a median of 2 prior lines of therapy. Video content above is prompted by the following:Please share your impressions of the efficacy outcomes reported in Ideate-Lung02: a 52.4% ORR, a 5.9-month median DOR, and a 12.2-month OS.
-
Nov 4, 2024 | 
targetedonc.com | Joshua K. Sabari
November 4, 2024Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1 and B7-H3 expression levels in all patients with SCLC. If B7-H3 testing becomes available, he would consider adding it to the biomarker assay, particularly at the time of diagnosis or recurrence. Video content above is prompted by the following:Is individual B7-H3 analysis currently available at your institution ?
-
Oct 29, 2024 | 
cancernetwork.com | Joshua K. Sabari |Sandip Patel
Putting Amivantamab Plus Lazertinib Into Practice Panelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.
